NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

印度的醫藥品市場分析、預測

India Pharmaceuticals Industry Analysis and Trends 2023

出版商 NAVADHI Market Research Pvt Ltd 商品編碼 818800
出版日期 內容資訊 英文 195 Pages
商品交期: 最快1-2個工作天內
價格
印度的醫藥品市場分析、預測 India Pharmaceuticals Industry Analysis and Trends 2023
出版日期: 2019年04月02日內容資訊: 英文 195 Pages
簡介

本報告提供印度的醫藥品市場調查,市場概要、市場背景,印度的醫藥品市場重要性,市場成長的各種影響因素分析,相關政策、法律規章,產業團體、政府機關,市場規模的變化、預測,進出口方案,市場風險,主要企業的簡介,目前趨勢與未來展望等彙整資料。

第1章 摘要整理

第2章 簡介:印度的醫藥品市場

  • 主要的產品、用語
  • 醫藥品
  • 創新的醫藥品
  • 罕見疾病用醫藥品
  • 學名藥
  • 產品學名藥
  • 品牌學名藥
  • 生物製藥
  • 生物相似藥
  • 成藥
  • 原料藥 (API:Active Pharmaceutical Ingredients)
  • 賦形劑
  • R&D階段
  • R&D投資:各產品部門
  • R&D投資:各階段
  • 價值鏈分析

第3章 印度的醫藥品市場需求

  • 人口的增加和高齡化
  • 貧困階級、中產階級的所得等級的上升
  • 醫藥品的安全保障

第4章 印度的醫藥品市場預測

  • 亞太地區的醫藥品市場預測
    • 印度的醫藥品市場預測

第5章 進出口方案

  • 出口方案
    • 出口額的變化
    • 外銷處主要5個國家
  • 進口方案
    • 進口額的變化
    • 進口商主要5個國家

第6章 市場成長的促進因素、抑制因素

第7章 相關政策

第8章 印度的醫藥品市場上風險

  • 專利失效、喪失智慧財產權保護的風險
  • 新產品的商業性成功的風險
  • R&D失敗的風險
  • 藥價管理的風險
  • 新的法律規章的遵守不全的風險
  • 複雜的製造工程和品管的風險
  • 電腦網路攻擊、資料洩漏的風險
  • 不穩定的匯率、利率的風險
  • 不穩定的全球政治經濟形勢的風險

第9章 產業團體

第10章 政府機關

第11章 主要企業的簡介

  • Abbott India Limited
  • Biocon Limited
  • CIPLA Limited
  • Dr. Reddy's Laboratories
  • Sun Pharmaceuticals Limited
  • Lupin Limited
  • Aurobindo Pharma Limited
  • Torrent Pharmaceuticals Limited
  • Divis Laboratories Limited
  • IPCA Laboratories Limited

第12章 競爭環境

  • 收益成果主要十大公司
  • 收益預測主要十大公司

第13章 市場分析

  • 大環境分析
  • 波特的五力分析
  • SWOT分析

第14章 現在、未來趨勢

  • 罕見疾病用醫藥品
  • 生物製藥、生物相似藥
  • 目前趨勢
目錄
Product Code: NAV0419001

India pharmaceutical market was the 11th largest pharmaceuticals market by value in the world in 2017. It is expected to register second highest CAGR growth among all countries till 2023 and improve it's raking to reach 9th position in the global pharmaceuticals market. Indian pharmaceutical market is expected to grow in the upcoming years despite recent slowdown due to price erosion in U.S. generics pharmaceuticals market, delay in approval of complex generics by US FDA (United States Food and Drug Administration) and aggressive drug price control mechanism like Government mandated drug price controls using drug price control order (DPCO) which is an order issued by the Government of India under Section 3 of the Essential Commodities Act, 1955 empowering it to fix and regulate the prices of essential bulk drugs and their formulations. The reasons are simple: aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases.

“India pharmaceuticals market is expected to be worth USD 33.18 billion by 2023.”

As per NAVADHI Market Research, the India pharmaceutical industry will we worth USD 33.18 billion and will rank 9th in global pharmaceuticals market by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

This growth is fueled by the growing and ageing population in India. More than 6% of Indian population is above 65 years of age and this number is expected to rise by 2023. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families is also driving the growth of Indian pharma industry. Indian people spend 64.21% of their health expenditure from out-of-pocket of which pharmaceuticals spend accounts for 51.67%. Other factors which are expected to contribute in the growth of Indian pharmaceuticals market are initiatives by Government of India like Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana and Pradhan Mantri Jan Arogya Yojana (PMJAY). In 2018, Government of India launched the world's largest public healthcare scheme Ayushman Bharat Yojana or Pradhan Mantri Jan Arogya Yojana (PMJAY) under National Health Protection Scheme (NHPS) which aims to provide free healthcare coverage of up to INR 0.5 million to around 100 million people. Also, under the aegis of Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana the Government of India as set up Jan Aushadhi Kendra (pharmacy stores) which provide quality medicines at affordable prices. These factors are expected to increase the access of pharmaceuticals to more people in world's second most populous nation.

On the other hand, Indian government's plan to widen the drug price control policies to patented and rare disease drugs along with tightening of rules by U.S. government like delay in approval of complex generics and price erosion in U.S. generics pharmaceuticals market (which is a major market for Indian pharmaceuticals companies) are expected to impact the growth prospect of the Indian pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the Indian pharma market as new drugs revenue form large part of pharma firm's revenue due to exclusivity of the drug.

U.S., South Africa, United Kingdom, Nigeria and Russia were the top five countries importing Indian pharmaceuticals and accounted for 48.58% of the total export revenues earned by Indian pharmaceutical industry in 2018.

The top ten Indian pharmaceutical importing countries (including Brazil, Australia, Kenya, Nepal and Philippines) accounted for 56.68% of the total export revenues earned by Indian pharmaceutical industry in 2018.

U.S., Germany, Switzerland, China and France were the top five countries exporting pharmaceutical products to Indian market and accounted for 48.80% of the total imports by Indian pharmaceutical industry in 2018.

The top ten Indian pharmaceutical importing countries (including Denmark, Belgium, Italy, Brazil and Indonesia) accounted for 71.77% of the total imports by Indian pharmaceutical market in 2018.

Navadhi has provided detailed company profiles including their position in Indian pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Indian pharmaceuticals market namely: Abbott India Limited, Aurobindo Pharma Limited, Biocon Limited, Cipla Limited, Divis Laboratories Limited, Dr. Reddy's Laboratories, IPCA Laboratories Limited, Lupin Limited, Sun Pharmaceuticals Limited and Torrent Pharmaceuticals Limited.

Scope of the ‘India Pharmaceuticals Industry Analysis and Trends 2023’ Report:

  • This report provides detailed information about Indian pharmaceuticals market including future market forecasts up to 2023.
  • This report identifies the need for focusing on Indian pharmaceuticals market.
  • The report identifies the growth drivers and inhibitors for Indian pharmaceuticals market.
  • This report provides information about policies related to pharmaceuticals industry in India.
  • This report provides information about industry associations and government bodies related to Indian pharmaceuticals industry.
  • The report identifies various risks associated with Indian pharmaceuticals market.
  • This report has detailed profiles 10 key players in Indian pharmaceuticals market covering their position in pharmaceuticals value chain, business strategy, financial performance, future forecasts and SWOT analysis.
  • This report provides competitive landscape among 10 key companies in Indian pharmaceuticals market.
  • This report provides PESTEL (political, economic, social, technological, environmental and legal) analysis for Indian pharmaceuticals market.
  • This report provides Porter's Five Forces analysis for Indian pharmaceuticals market.
  • This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Indian pharmaceuticals market.
  • This report provides information about current and future trends for Indian pharmaceuticals market.
  • This report provides information about current and future trends for U.S. pharmaceuticals market.

Countries Covered:

  • India.

Companies Covered:

  • Abbott India Limited
  • Aurobindo Pharma Limited
  • Biocon Limited
  • Cipla Limited
  • Divis Laboratories Limited
  • Dr. Reddy's Laboratories
  • IPCA Laboratories Limited
  • Lupin Limited
  • Sun Pharmaceuticals Limited
  • Torrent Pharmaceuticals Limited

Table of Contents

1. Executive Summary

  • Scope of the India Pharmaceuticals Industry Analysis and Trends 2023 Report
  • Research Methodology

2. Introduction of Indian Pharmaceuticals Market

  • Key Product Terms Used in Pharmaceuticals Industry
  • Pharmaceuticals
  • Innovative Drugs
  • Orphan Drugs
  • Generic Drugs
  • Commodity Generic Drugs
  • Branded Generic Drugs
  • Biologics
  • Biosimilars
  • Over-the-counter (OTC) Drugs
  • Active Pharmaceutical Ingredients (APIs)
  • Excipients
  • Research and Development (R&D) Phases of Pharmaceuticals Industry
  • Industry-Wise Research and Development (R&D) Investment
  • Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
  • Indian Pharmaceuticals Industry Value Chain Analysis

3. Need for Indian Pharmaceuticals Market

  • 3.1. Rising & Ageing Population
  • 3.2. Increasing Income Levels of Poor & Middle-Class Families
  • 3.3. Drug Security

4. Forecast for India Pharmaceuticals Market 2023

  • 4.1. Forecast for Asia Pacific Pharmaceuticals Market 2018-2023
    • 4.1.1. Forecast for India Pharmaceuticals Market 2018-2023

5. EXIM Scenario in Indian Pharmaceuticals Market

  • 5.1. Export Scenario of Indian Pharmaceutical Products Market
    • 5.1.1. Value of Pharmaceutical Products Exports from India 2008-09 to 2018-19 (Apr-Jan) in USD million
    • 5.1.2. Top 5 Nations Importing Indian Pharmaceutical Products
  • 5.2. Import Scenario of Indian Pharmaceutical Products Market
    • 5.2.1. Value of Pharmaceutical Products Imports in India 2008-09 to 2018-19 (Apr-Jan) in USD million
    • 5.2.2. Top 5 Nations Exporting Pharmaceutical Products to India

6. Growth Drivers and Inhibitors for India Pharmaceuticals Market

7. Policies Related to Pharmaceuticals Industry in India

  • 7.1. Central Government Policies
    • 7.1.1. Essential Commodities Act 1955
    • 7.1.2. Drugs and Cosmetics Act 1940 (As amended in June 2005)
    • 7.1.3. National Pharmaceutical Pricing Policy 2012
    • 7.1.4. Drug Price Control Orders (DPCO)
    • 7.1.5. Drug Policy 1986
    • 7.1.6. Pharmaceutical Policy - 2002
  • 7.2. Guidelines related to Clinical Trial in India
  • 7.3. Guidelines related to Marketing in Indian Pharmaceuticals Industry

8. Risks Associated with Indian Pharmaceuticals Market

  • 8.1. Risk of Patent Expiry and Loss of Intellectual Property Protection
  • 8.2. Risk of Commercial Success of New Products
  • 8.3. Risk of Failed Research and Development Effort
  • 8.4. Risk of Drug Price Controls
  • 8.5. Risk of Failure to Comply with New Laws and Regulations
  • 8.6. Risk of Quality Control During Complex Manufacturing Process
  • 8.7. Risk of Cyber-Attacks and Data Breach
  • 8.8. Risk of Volatile Currency Exchange Rates and Interest Rates
  • 8.9. Risk of Unstable Global Political and Economic Conditions

9. Industry Associations Related to Indian Pharmaceuticals Market

  • 9.1. Indian Drug Manufacturers' Association (IDMA)
  • 9.2. Indian Pharma Machinery Manufacturers Association (IPMMA)
  • 9.3. Indian Pharmaceutical Association (IPA)
  • 9.4. Organisation of Pharmaceutical Producers of India (OPPI)
  • 9.5. Association of Indian Medical Device Industry (AIMED)

10. Government Bodies Related to Indian Pharmaceuticals Market

  • 10.1. Department of Pharmaceuticals
  • 10.2. Ministry of Chemicals & Fertilizers
  • 10.3. National Pharmaceutical Pricing Authority (NPPA)

11. Profile of Key Players in Indian Pharmaceuticals Market

  • 11.1. Abbott India Limited
    • 11.1.1. Company Profile
    • 11.1.2. Abbott India in Pharma Manufacturing Value Chain
    • 11.1.3. Abbott India: Financial Performance
    • 11.1.4. Abbott India: Business Strategy
      • 11.1.4.1. Product Level Strategy
    • 11.1.5. SWOT Analysis of Abbott India
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 11.1.6. Key Customers of Abbott India
  • 11.2. Biocon Limited
    • 11.2.1. Company Profile
    • 11.2.2. Biocon Limited in Pharmaceutical Manufacturing Value Chain
    • 11.2.3. Biocon Limited: Financial Performance
    • 11.2.4. Biocon Limited: Business Strategy
      • 11.2.4.1. Product Level Business Strategy
      • 11.2.4.2. Service Level Business Strategy
    • 11.2.5. SWOT Analysis of Biocon Limited
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 11.2.6. Key Customers of Biocon Limited
  • 11.3. CIPLA Limited
    • 11.3.1. Company Profile
    • 11.3.2. CIPLA Limited in Pharmaceutical Manufacturing Value Chain
    • 11.3.3. CIPLA Limited: Financial Performance
    • 11.3.4. CIPLA Limited: Business Strategy
      • 11.3.4.1. Product Level Business Strategy
      • 11.3.4.2. Service Level Business Strategy
    • 11.3.5. SWOT Analysis of CIPLA Limited
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 11.3.6. Key Customers of CIPLA Limited
  • 11.4. Dr. Reddy's Laboratories
    • 11.4.1. Company Profile
    • 11.4.2. Dr. Reddy's Laboratories in Pharma Manufacturing Value Chain
    • 11.4.3. Dr. Reddy's Laboratories: Financial Performance
    • 11.4.4. Dr. Reddy's Laboratories: Business Strategy
      • 11.4.4.1. Product Level Business Strategy
      • 11.4.4.2. Service Level Business Strategy
    • 11.4.5. SWOT Analysis of Dr. Reddy's Laboratories
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 11.5. Sun Pharmaceuticals Limited
    • 11.5.1. Company Profile
    • 11.5.2. Sun Pharmaceuticals Limited in Pharma Manufacturing Value Chain
    • 11.5.3. Sun Pharmaceuticals Limited: Financial Performance
    • 11.5.4. Sun Pharmaceuticals Limited: Business Strategy
    • 11.5.5. SWOT Analysis of Sun Pharmaceuticals Limited
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 11.5.6. Key customers of Sun Pharmaceuticals Limited
  • 11.6. Lupin Limited
    • 11.6.1. Company Profile
    • 11.6.2. Lupin Limited in Pharma Manufacturing Value Chain
    • 11.6.3. Lupin Limited: Financial Performance
    • 11.6.4. Lupin Limited: Business Strategy
      • 11.6.4.1. Product Level Strategy
    • 11.6.5. SWOT Analysis of Lupin Limited
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 11.7. Aurobindo Pharma Limited
    • 11.7.1. Company Profile
    • 11.7.2. Aurobindo Pharmaceuticals in Pharma Manufacturing Value Chain
    • 11.7.3. Aurobindo Pharmaceuticals: Financial Performance
    • 11.7.4. Aurobindo Pharmaceuticals: Business Strategy
    • 11.7.5. SWOT Analysis of Aurobindo Pharmaceuticals
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 11.8. Torrent Pharmaceuticals Limited
    • 11.8.1. Company Profile
    • 11.8.2. Torrent Pharmaceuticals in Pharma Manufacturing Value Chain
    • 11.8.3. Torrent Pharmaceuticals: Financial Performance
    • 11.8.4. Torrent Pharmaceuticals: Business Strategy
    • 11.8.5. SWOT Analysis of Torrent Pharmaceuticals Limited
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 11.8.6. Key Customers of Torrent Pharmaceuticals
  • 11.9. Divis Laboratories Limited
    • 11.9.1. Company Profile
    • 11.9.2. Divis Laboratories Limited in Pharma Manufacturing Value Chain
    • 11.9.3. Divis Laboratories: Financial Performance
    • 11.9.4. Divis Laboratories: Business Strategy
    • 11.9.5. SWOT Analysis of Divis Laboratories Limited
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 11.10. IPCA Laboratories Limited
    • 11.10.1. Company Profile
    • 11.10.2. IPCA Laboratories Limited in Pharmaceutical Manufacturing Value Chain
    • 11.10.3. IPCA Laboratories Limited: Financial Performance
    • 11.10.4. IPCA Laboratories Limited: Business Strategy
    • 11.10.5. SWOT Analysis of IPCA Laboratories Limited
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 11.1.10.6. Key Customers of IPCA Laboratories Limited

12. Competitive Landscape in Indian Pharmaceuticals Market

  • 12.1. Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Overall Revenue for FY2018
  • 12.2. Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Forecast Revenue

13. Analysis of India Pharmaceuticals Market

  • 13.1. PESTLE Analysis of India Pharmaceuticals Market
  • 13.2. Porter's Five Forces Analysis of India Pharmaceuticals Market
  • 13.3. SWOT Analysis of India Pharmaceuticals Market
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats

14. Current and Future Trends in Indian Pharmaceuticals Market

  • Orphan Drugs
  • Biologics and Biosimilars
  • Current Trends
    • 1. Increasing Severity of Drug Price Controls
    • 2. Greater Focus on Rare Diseases / Orphan Drugs
    • 3. Increasing Development of Nucleic Acids as Therapeutics
    • 4. Increasing Focus on Cell Therapy
    • 5. Implantables (Bioelectronics) and Electroceuticals are Expected to Become Mainstream
    • 6. Use of 3D Printing to Reduce Cost and Improve Production Efficiency of Biologics
    • 7. Increasing Use of Big Data and Artificial Intelligence (AI) in Drug Discovery
  • List of Exhibits
  • Notes
  • Company Information

List of Exhibits

  • Exhibit 2.1: Research and Development Phases of Pharmaceuticals Industry
  • Exhibit 2.2: Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
  • Exhibit 2.3: Phase-Wise Research and Development Investment in Pharmaceuticals Industry
  • Exhibit 2.4: Indian Pharmaceuticals Industry Value Chain Analysis
  • Exhibit 3.1: India Population Forecast 2016-2023 (in millions)
  • Exhibit 3.2: Purchasing Power Parity Based Per Capita GDP Forecast for India 2016-2023 (in USD)
  • Exhibit 4.1: Forecast for Asia Pacific Pharmaceuticals Market 2018-2023 (in USD billion)
  • Exhibit 4.2: Country-wise Market Share in Asia Pacific Pharmaceuticals Market in 2017 (in %)
  • Exhibit 4.3: Population Forecast for India 2016-2023 (in millions)
  • Exhibit 4.4: India Pharmaceuticals Market Analysis
  • Exhibit 4.5: Forecast for India Pharmaceuticals Market 2018-2023 (in USD billion)
  • Exhibit 5.1: Export Value of Pharmaceutical Products from India (in USD million) from FY 2008-09 to FY 2018-19 (Apr-Jan)
  • Exhibit 5.2: Top 5 Countries Importing Indian Pharmaceutical Products (in USD million) in FY 2017-18
  • Exhibit 5.3: Import Value of Pharmaceutical Products in India (in US$ million) from FY 2008-09 to FY 2018-19 (Apr-Jan)
  • Exhibit 5.4: Top 5 Countries Exporting Pharmaceutical Products to India (in USD million) in FY 2017-18
  • Exhibit 6.1: Growth Drivers and Inhibitors for India Pharmaceuticals Market
  • Exhibit 7.1: Code for Marketing practices in Indian Pharmaceuticals Industry
  • Exhibit 8.1: Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
  • Exhibit 9.1: Key information of IDMA
  • Exhibit 9.2: Contact details of IDMA
  • Exhibit 9.3: Key information of IPMMA
  • Exhibit 9.4: Contact details of IPMMA
  • Exhibit 9.5: Key Information of IPA
  • Exhibit 9.6: Contact details of IPA
  • Exhibit 9.7: Key information of OPPI
  • Exhibit 9.8: Contact details of OPPI
  • Exhibit 9.9: Contact information for AIMED
  • Exhibit 11.1: Key Information of Abbott India
  • Exhibit 11.2: Contact Information of Abbott India
  • Exhibit 11.3: Abbott India in Pharma Manufacturing Value chain
  • Exhibit 11.4: Abbott India Limited Revenue 2014-18 (in INR billion)
  • Exhibit 11.5: Abbott India Growth Rate 2014-2018 (in %)
  • Exhibit 11.6: Estimated Year wise Abbott India Revenue 2019-2023 (in INR billion)
  • Exhibit 11.7: Top performing brands of Abbott India 2018
  • Exhibit 11.8: Top New Products of Abbott India 2018
  • Exhibit 11.9: SWOT Analysis of Abbott India
  • Exhibit 11.10: Key Information of Biocon Limited
  • Exhibit 11.11: Contact Information of Biocon Limited
  • Exhibit 11.12: Biocon Ltd in Pharma Manufacturing Value Chain
  • Exhibit 11.13: Biocon Limited Revenue 2013-2018 (in INR billion)
  • Exhibit 11.14: Year-wise Biocon Limited Revenue Growth 2013-18 (in %)
  • Exhibit 11.15: Category Wise Revenue Breakup for Biocon Limited 2018 (in INR billion)
  • Exhibit 11.16: Estimated Year wise Biocon Limited Revenue 2019-2023 (in INR billion)
  • Exhibit 11.17: Key Products of Biocon Limited
  • Exhibit 11.18: Key Services Offered by Biocon Limited
  • Exhibit 11.19: SWOT Analysis of Biocon Limited
  • Exhibit 11.20: Key Information of Cipla Limited
  • Exhibit 11.21: Contact Information of Cipla Limited
  • Exhibit 11.22: Cipla Limited in Pharmaceutical Manufacturing Value Chain
  • Exhibit 11.23: Cipla Limited Revenue 2014-2018 (in INR billion)
  • Exhibit 11.24: Year-wise Cipla Limited Revenue Growth 2014-2018 (in %)
  • Exhibit 11.25: Estimated Cipla Ltd. Revenue (in INR bn)
  • Exhibit 11.26: Key Products of Cipla Limited
  • Exhibit 11.27: Key Services of Cipla Limited
  • Exhibit 11.28: SWOT Analysis of Cipla Limited
  • Exhibit 11.29: Key Information of Dr. Reddy's Laboratories
  • Exhibit 11.30: Contact Information of Dr. Reddy's Laboratories
  • Exhibit 11.31: Dr. Reddy's Laboratories in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 11.32: Dr. Reddy's Laboratories Revenue 2013-2017 (in INR million)
  • Exhibit 11.33: Year-wise Dr. Reddy's Laboratories Revenue Growth 2014-17 (in %)
  • Exhibit 11.34: Dr. Reddy's Laboratories Domestic Revenue 2014-2017 (in INR billion)
  • Exhibit 11.35: Year-wise Dr. Reddy's Laboratories Domestic Revenue Growth 2015-2017 (in %)
  • Exhibit 11.36: Dr. Reddy's Laboratories Export Revenue 2014-2017 (in INR billion)
  • Exhibit 11.37: Year-wise Dr. Reddy's Laboratories Export Revenue Growth 2015-2017 (in %)
  • Exhibit 11.38: Source wise Revenue share of Dr. Reddy's Lab. (in %)
  • Exhibit 11.39: Source wise Revenue CAGR growth forecast for Dr. Reddy's Lab Ltd. 2018-23 (in %)
  • Exhibit 11.40: Forecast of Dr. Reddy's Laboratories Ltd, 2018-23 (in INR bn)
  • Exhibit 11.41: Growth forecast of Domestic Revenue for Dr. Roddy's Laboratories Ltd. 2018-23 (in INR bn)
  • Exhibit 11.42: Growth forecast of Export revenue for Dr. Reddy's Laboratories ltd. Market 2018-23 (in INR bn)
  • Exhibit 11.43: Key Products of Dr. Reddy's Laboratories
  • Exhibit 11.44: Key Services of Dr. Reddy's Laboratories
  • Exhibit 11.45: SWOT Analysis of Dr. Reddy's Laboratories
  • Exhibit 11.46: Key Information of Sun Pharmaceuticals Limited
  • Exhibit 11.47: Contact Information of Sun Pharmaceuticals Limited
  • Exhibit 11.48: Sun Pharmaceuticals Limited in Pharma Manufacturing Value Chain
  • Exhibit 11.49: Sun Pharmaceuticals Limited Revenue 2014-2018 (in INR billion)
  • Exhibit 11.50: Year-wise Sun Pharmaceuticals Limited Revenue Growth 2015-18 (in %)
  • Exhibit 11.51: Sun Pharmaceuticals Limited India Market Revenue 2014-2018 (in INR million)
  • Exhibit 11.52: Year-wise Sun Pharmaceuticals Limited India Market Revenue Growth 2015-2018 (in %)
  • Exhibit 11.53: Sun Pharmaceuticals Limited Export Revenue 2016-2018 (in INR billion)
  • Exhibit 11.54: Year-wise Sun Pharmaceuticals Limited US sales Revenue Growth (in %)
  • Exhibit 11.55: Sun Pharmaceuticals Industries Ltd, emerging markets Revenue (in INR bn)
  • Exhibit 11.56: Year wise sun Pharmaceutical Industries Ltd. Emerging markets Revenue growth (in %)
  • Exhibit 11.57: Sun Pharmaceuticals Industries Ltd. Rest of World Revenue (in INR bn)
  • Exhibit 11.58: Year wise Sun Pharmaceuticals Industries Ltd. Rest of World Revenue Growth (in %)
  • Exhibit 11.59: Source-wise Revenue Share of Sun Pharmaceutical Industries Ltd. (in %)
  • Exhibit 11.60: Source wise Revenue CAGR Growth Forecast for Sun Pharmaceutical Industries Ltd. 2019-23 (in %)
  • Exhibit 11.61: Forecast of Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
  • Exhibit 11.62: Forecast of India Market Revenue for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
  • Exhibit 11.63: Forecast of US Market Revenue for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
  • Exhibit 11.64: Forecast of Emerging Markets for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
  • Exhibit 11.65: Forecast of RoW Market for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
  • Exhibit 11.66: Key Products of Sun Pharmaceuticals Limited
  • Exhibit 11.67: SWOT Analysis of Sun Pharmaceuticals Limited
  • Exhibit 11.68: Key Information of Lupin Limited
  • Exhibit 11.69: Contact Information of Lupin Limited
  • Exhibit 11.70: Lupin Limited in Pharma Manufacturing Value Chain
  • Exhibit 11.71: Lupin Limited Revenue 2014-2018 (in INR billion)
  • Exhibit 11.72: Year-wise Lupin Limited Revenue Growth 2014-18 (in %)
  • Exhibit 11.73: Lupin Limited India Market Revenue 20104-2018 (in INR billion)
  • Exhibit 11.74: Year-wise Lupin Limited Domestic Revenue Growth 2015-2018 (in %)
  • Exhibit 11.75: Lupin Limited Export Revenue 2010-2014 (in INR billion)
  • Exhibit 11.76: Year-wise Lupin Limited US Market Revenue Growth 2017-2018 (in %)
  • Exhibit 11.77: Lupin Ltd. Rest of World (RoW) Revenue (in INR bn)
  • Exhibit 11.78: Year wise Lupin Ltd. Rest of World Revenue Growth (in %)
  • Exhibit 11.79: Country wise Revenue share of Lupin Ltd. (in %)
  • Exhibit 11.80: Country wise Revenue CAGR Growth Forecast for Lupin Ltd. 2019-23 (in %)
  • Exhibit 11.81: Forecast of Lupin Ltd. 2019-23 (in INR bn)
  • Exhibit 11.82: Growth Forecast of India Market for Lupin Ltd. Market 2019-23 (in INR bn)
  • Exhibit 11.83: Growth Forecast of US market for Lupin Ltd. 2019-23 (in INR bn)
  • Exhibit 11.84: Growth Forecast of rest of world for Lupin Ltd. 2019-23 (in INR bn)
  • Exhibit 11.85: Key Products of Lupin Limited
  • Exhibit 11.86: SWOT Analysis of Lupin Limited
  • Exhibit 11.87: Key Information of Aurobindo Pharma Limited
  • Exhibit 11.88: Contact Information of Aurobindo Pharma Limited
  • Exhibit 11.89: Aurobindo Pharma Limited in Pharma Manufacturing Value Chain
  • Exhibit 11.90: Aurobindo Pharma Limited Revenue 2010-2014 (in INR billion)
  • Exhibit 11.91: Year-wise Aurobindo Pharma Limited Revenue Growth 2010-14 (in %)
  • Exhibit 11.92: Source wise revenue share of Aurobindo Pharma Ltd. (in %)
  • Exhibit 11.93: Source wise Revenue CAGR growth forecast for Aurobindo Pharma Ltd. 2018-23 (in %)
  • Exhibit 11.94: Forecast of Aurobindo Pharma Ltd. 2018-23 (in INR billions)
  • Exhibit 11.95: Growth Forecast of US Market for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
  • Exhibit 11.96: Growth forecast of Rest of World for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
  • Exhibit 11.97: SWOT Analysis of Aurobindo Pharmaceuticals
  • Exhibit 11.98: Key Information of Torrent Pharmaceuticals Limited
  • Exhibit 11.99: Contact Information of Torrent Pharmaceuticals Limited
  • Exhibit 11.100: Torrent Pharmaceuticals Limited in Pharma Manufacturing Value Chain
  • Exhibit 11.101: Torrent Pharmaceuticals Limited Revenue 2013-2018 (in INR billion)
  • Exhibit 11.102: Year-wise Torrent Pharmaceuticals Limited Revenue Growth 2014-18 (in %)
  • Exhibit 11.103: Torrent Pharma Ltd, India Revenue (in INR bn)
  • Exhibit 11.104: Year wise Torrent Pharma Ltd. India Revenue Growth (in %)
  • Exhibit 11.105: Torrent Pharma Ltd. US sales Revenue (in INR bn)
  • Exhibit 11.106: Year wise Torrent Pharma Ltd. US sales Revenue Growth (in %)
  • Exhibit 11.107: Torrent Pharma Ltd. Germany Revenue (in INR bn)
  • Exhibit 11.108: Year wise Torrent Pharma Ltd. Germany Revenue Growth (in %)
  • Exhibit 11.109: Torrent Pharma Ltd. Brazil Revenue (in INR bn)
  • Exhibit 11.110: Year wise Torrent Pharma Ltd. Brazil Revenue Growth (in %)
  • Exhibit 11.111: Torrent Pharma Ltd. Others Revenue (in INR bn)
  • Exhibit 11.112: Year wise Torrent Pharma Ltd. Others Revenue Growth (in %)
  • Exhibit 11.113: Source Wise Revenue Share of Torrent Parma Ltd, (in %)
  • Exhibit 11.114: Source wise Revenue CAGR Growth Forecast for Torrent Pharma Ltd. 2019-23 (in %)
  • Exhibit 11.115: Forecast of Torrent Pharma Ltd. 2019-23 (in INR bn)
  • Exhibit 11.116: Forecast of India Market Revenue for Torrent Pharma Ltd. 2019-23 (in INR bn)
  • Exhibit 11.117: Forecast of US Market Revenue for Torrent Pharma Ltd. 2019-23 (in INR bn)
  • Exhibit 11.118: Forecast of Germany for Torrent Pharma Ltd. 2019-23 (in INR bn)
  • Exhibit 11.119: Forecast of Brazil for Torrent Pharma Ltd. 2019-23 (in INR bn)
  • Exhibit 11.120: Forecast of Others for Torrent Pharma Ltd. 2019-23 (in INR bn)
  • Exhibit 11.121: Key Products of Torrent Pharmaceuticals Limited
  • Exhibit 11.122: SWOT Analysis of Torrent Pharmaceuticals Limited
  • Exhibit 11.123: Key Information of Divis Laboratories Limited
  • Exhibit 11.124: Contact Information of Divis Laboratories Limited
  • Exhibit 11.125: Divis Laboratories Limited in Pharma Manufacturing Value Chain
  • Exhibit 11.126: Divis Laboratories Limited Revenue 2013-2018 (in INR billion)
  • Exhibit 11.127: Year-wise Divis Laboratories Limited Revenue Growth 2014-18 (in %)
  • Exhibit 11.128: Divis Lab Ltd, Export Revenue (in INR bn)
  • Exhibit 11.129: Year wise Divis Lab Ltd. Export Revenue Growth (in %)
  • Exhibit 11.130: Divis Lab Ltd. India Sales Revenue (in INR bn)
  • Exhibit 11.131: Year wise Divis Lab Ltd. India Sales Revenue growth (in %)
  • Exhibit 11.132: Source wise Revenue Share of Divis Lab Ltd. (%)
  • Exhibit 11.133: Source wise Revenue CAGR Growth Forecast for Divis Lab Ltd. 2019-23 (in %)
  • Exhibit 11.134: Forecast of Divis Lab Ltd. 2019-23 (in INR bn)
  • Exhibit 11.135: Forecast of Rest of World Revenue for Divis Lab Ltd. 2019-23 (in INR bn)
  • Exhibit 11.136: Forecast of India Market Revenue for Divis Lab Ltd. 2019-23 (in INR bn)
  • Exhibit 11.137: Key Products of Divis Laboratories Limited
  • Exhibit 11.138: SWOT Analysis of Divis Laboratories Limited
  • Exhibit 11.139: Key Information of Ipca Laboratories Limited
  • Exhibit 11.140: Contact details of Ipca Laboratories Limited
  • Exhibit 11.141: Laboratories Limited in Pharma Manufacturing Value Chain
  • Exhibit 11.142: IPCA Laboratories Limited Revenue 2013-2018 (in INR billion)
  • Exhibit 11.143: Year-wise IPCA Laboratories Limited Revenue Growth 2014-2018 (in %)
  • Exhibit 11.144: Estimated Year wise IPCA Laboratories Limited Revenue 2013-2018 (in INR billion)
  • Exhibit 11.145: Estimated Year-wise IPCA Laboratories Limited Revenue Growth 2014-2018 (in %)
  • Exhibit 11.146: IPCA Laboratories Limited Revenue by Geography 2014 (in INR billion)
  • Exhibit 11.147: Year wise IPCA Lab Ltd. Export Sales Revenue Growth (in %)
  • Exhibit 11.148: Source wise Revenue share of IPCA Lab Ltd. (in %)
  • Exhibit 11.149: Source wise Revenue CAGR growth forecast for IPCA Lab. Ltd. 2019-23 (in %)
  • Exhibit 11.150: Forecast of IPCA Lab. Ltd. 2019-23 (in INR bn)
  • Exhibit 11.151: Forecast of India Market Revenue for IPCA Lab Ltd. 2019-23 (in INR bn)
  • Exhibit 11.152: Forecast of Export Market Revenue for IPCA Lab ltd. 2019-23 (in INR bn)
  • Exhibit 11.153: Key Products of IPCA Laboratories Limited
  • Exhibit 11.154: Key Services of IPCA Laboratories Limited
  • Exhibit 11.155: SWOT Analysis of IPCA Laboratories Limited
  • Exhibit 11.156: Key Customers of IPCA Laboratories Limited
  • Exhibit 12.1: Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Overall Revenue for FY2018 (in INR billion)
  • Exhibit 12.2: Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Forecast Revenue (in INR billion)
  • Exhibit 13.1: PESTEL Analysis of the Indian Pharmaceuticals Industry
  • Exhibit 13.2: Porter's Five Forces Analysis for India Pharmaceuticals Market
  • Exhibit 13.3: SWOT Analysis for India Pharmaceuticals Market"